FDA approves first biosimilar for treatment of adult patients with non-Hodgkin ’s lymphoma
The FDA approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin ’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 28, 2018 Category: American Health Source Type: news

Truxima Approved as First Biosimilar to Non-Hodgkin's Lymphoma Drug
WEDNESDAY, Nov. 28, 2018 -- Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin ' s lymphoma drug Rituxan, the agency said Wednesday. A biosimilar is a biological product that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 28, 2018 Category: General Medicine Source Type: news

Rituximab for Nephrotic Syndrome in Kids: A Note of Caution Rituximab for Nephrotic Syndrome in Kids: A Note of Caution
Dr William Basco hesitates to recommend an immediate switch to rituximab as a steroid-sparing agent in children with nephrotic syndrome.Medscape Pediatrics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 27, 2018 Category: Consumer Health News Tags: Pediatrics Viewpoint Source Type: news

Efficacy of Rituximab Biosimilar in Follicular Lymphoma
A phase III study looks at the efficacy and safety of rituximab biosimilar CT-P10 in patients with follicular lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - November 27, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Rituximab Promising in Childhood Vasculitis
(MedPage Today) -- Treatment was steroid-sparing in Hemoch-Schonlein purpura (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - November 15, 2018 Category: Pediatrics Source Type: news

Sandoz abandons Rituxan biosim in U.S.
Sandoz announced that it will no longer pursue FDA approval for its biosimilar rituximab, GP2013. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 9, 2018 Category: Pharmaceuticals Source Type: news

Hypogammaglobulinemia Screening Needed for Patients Receiving Rituximab Hypogammaglobulinemia Screening Needed for Patients Receiving Rituximab
Patients being considered for rituximab therapy should be screened for hypogammaglobulinemia before and after rituximab administration, researchers report.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 8, 2018 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

Treating Advanced Indolent Follicular Lymphoma Without Chemotherapy
New research evaluated whether symptomatic indolent follicular lymphoma requires new long-term therapy after first-line rituximab without chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - November 8, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Novartis scraps U.S. filing for biosimilar rituximab
Novartis International AG ’s Sandoz division will abandon its quest to win U.S. approval for rituximab. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 5, 2018 Category: Pharmaceuticals Source Type: news

Novartis abandons effort for U.S. approval of biosimilar rituximab
Novartis International AG said on Friday that its Sandoz division is abandoning an effort to gain U.S. regulatory approval for a biosimilar of rituximab, a medication used to treat certain cancer and rheumatoid arthritis. (Source: Reuters: Health)
Source: Reuters: Health - November 2, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Ibrutinib/BR Combo Improves Survival in CLL
Long-term data from the phase III HELIOS trial indicates ibrutinib plus bendamustine and rituximab improve survival outcomes in CLL patients. (Source: CancerNetwork)
Source: CancerNetwork - November 1, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

CD47 Blocker Reverses Rituximab Resistance in Lymphoma
(MedPage Today) -- Overall response rate of 50% in previously refractory patients (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 1, 2018 Category: Hematology Source Type: news

AbbVie Receives European Commission Approval of VENCLYXTO(R) (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
The approval is based on the MURANO Phase 3 clinical trial, in which VENCLYXTO® plus rituximab reduced the risk of disease progression or death by 83 percent and overall survival was prolonged compared to bendamustine in combination with rituximab, a s... Biopharmaceuticals, Oncology, Regulatory AbbVie, VENCLYXTO, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2018 Category: Pharmaceuticals Source Type: news

Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Media News)
Source: Roche Media News - November 1, 2018 Category: Pharmaceuticals Source Type: news

Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - November 1, 2018 Category: Pharmaceuticals Source Type: news